Lyora Therapeutics
Providence, United States
◆ Total Raised
$2.5M
◆ Stage
pre-seed
◆ Location
Providence, United States
◆ Founded
2026
◆ Team size
1-10
◆ Links
◆ About Lyora Therapeutics
Biotech company developing genetic medicines targeting the root cause of inherited retinal diseases.
◆ What sets it apart
It focuses on root-cause genetic medicines for inherited retinal diseases using de-risked, validated biology and locally delivered durable therapies.
◆ Sectors
◆ Business
Modelbiotech
Customerpatients with inherited retinal diseases and the clinicians or specialty centers that treat them
◆ Notable
- Launched publicly in July 2026 with seed funding
- Introduced lead program LYA-101 for retinitis pigmentosa caused by PRPF31 variants
- Introduced LYA-102 for Usher syndrome type 2 using optimized CRISPR technology
- Positioned as a Providence-based biotech startup
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Lyora Therapeutics do?
Biotech company developing genetic medicines targeting the root cause of inherited retinal diseases.
Where is Lyora Therapeutics based?
Lyora Therapeutics is based in Providence, United States, founded in 2026.
How much has Lyora Therapeutics raised?
Lyora Therapeutics has raised $2.5M in tracked funding and is currently at the pre-seed stage.
Who has invested in Lyora Therapeutics?
Investors in Lyora Therapeutics include Seed investors not clearly identified in the available sources.